CD33 and acute myeloid leukemia: Another anti-CD33-based ADC, vadastuxumab, which is based on the potent DNA minor groove-binding agent pyrrolobenzodiazepine, showed promise in preclinical models of AML, but the trial was discontinued due to safety issues (NCT02785900).